Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males \& females, 18-77 years old inclusive, with type 2 diabetes and with inadequate glycemic control~* Drug naive or treated with anti-diabetic medication for \< 24 weeks since original diagnosis~* C-peptide ≥ 1.0 ng/mL~* Body Mass Index ≤ 45.0 kg/m~* Serum creatinine \< 1.50 mg/dL for men or \< 1.40 mg/dL for women~Exclusion Criteria:~* AST and/or ALT \>3.0 times the upper limit of normal (ULN)~* Serum total bilirubin \> 2.0 mg/dL~* Creatine kinase \> 3X the upper limit of normal (ULN)~* Symptoms of severely uncontrolled diabetes~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
- Arm 2 (Type: EXPERIMENTAL): Dapagliflozin (5 mg)
- Arm 3 (Type: ACTIVE_COMPARATOR): Metformin XR (500 mg up to 2000 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).